ANAPTYSBIO, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $2.69M, a 1225.12% increase year-over-year.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $203.00K, a 22.81% decline year-over-year.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $592.00K, a 733.80% increase year-over-year.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $167.00K, a 363.89% increase year-over-year.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $11.87M, a 362.83% increase from fiscal 2021.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $2.56M, a 415.90% increase from fiscal 2020.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $497.00K, a 83.47% decline from fiscal 2019.
- ANAPTYSBIO, INC. stock issued during period, value, stock options exercised for fiscal 2019 was $3.01M, a 4.81% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-12-31 | $11.87M 10-K · filed 2023-03-01 | |
| 2022-09-30 | $2.69M 10-Q · filed 2022-11-08 | |
| 2021-12-31 | $2.56M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $203.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $592.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $167.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $497.00K 10-K · filed 2023-03-01 | |
| 2020-09-30 | $263.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $71.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $36.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $3.01M 10-K · filed 2022-03-07 | |
| 2019-09-30 | $454.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $215.00K 10-Q · filed 2020-11-04 | |
| 2019-03-31 | $574.00K 10-Q · filed 2020-11-04 | |
| 2018-12-31 | $2.87M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $669.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $1.40M 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $72.00K 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $979.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $31.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | $160.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |